Sequential combined treatment of heroin addicted patients in portugal with naltrexone and family therapy

European Addiction Research

Volumn 3, Issue 3, 1997, Pages 138-145

  Neto, Domingos ^a   Xavier, Miguel ^a   Aguiar, Pedro ^b   David, Mário ^c   Sardinha, Luís ^a   De Almeida, Caldas ^a  

^a S Francisco Xavier Hospital   (Portugal)

^b INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^c Drug Addiction Treatment Center   (Portugal)

Author keywords

Family therapy; Heroin addiction; Naltrexone

Indexed keywords

NALTREXONE; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DEPRESSION; DETOXIFICATION; FAMILY THERAPY; FEMALE; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PORTUGAL; PRIORITY JOURNAL; URINALYSIS;

EID: 0030754544     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000259167     Document Type: Article

References (42)

1. Rawson RA, Washton AM, Resnick RB, et al: Clonidine hydrochloride detoxification from methadone treatment - the value of naltrexone aftercare. Adv Alcohol Subst Abuse 1984:3:41-49.
2. Anton RF, Hogan I, Jalali B, Riordan CE, Kleber HD: Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug Alcohol Depend 1981;8:157-168.
3. Ginzburg HM: Naltrexone, its clinical utility. Adv Alcohol Subst Abuse 1985;6:83-101.
4. O'Brien CP, Greenslein DA, Mintz A, Woody G: Clinical experience with naltrexone. Am J Alcohol Abuse 1975;2:365-377.
5. Sideroff SI, Charuvastra VC, Jarvick ME: Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse 1979:5:415-423.
6. Greenstein RA, Arndt IC, McLellan AT, O’Brien CP, Evans B: Naltrexone: A clinical perspective. J Clin Psychiatry 1984:45:25-28.
7. Tennant FS, Rawson RA, Cohen AJ, Mann A: Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry 1984;45: 42-45.
8. Capone TA, Brahen LS, Brahen R: Psychoanalytic and behavioral considerations in antagonist and methadone programs. J Contemp Psy-chothcr 1978:9:2:139-150.
9. Fram DH, Marmo J, Holden R: Naltrexone treatment - the problem of patient acceptance. J Subst AbuscTreat 1989:6:1 19-122.
10. Lopez Ibor Jr JL, Cobos JP, Ochoa E: The medical model in the management of heroin dependence; in Stefanis CN, Rabavilas AD, Soldatos CR (eds): Classification and Psychopathology; Child Psychiatry; Substance Use. Proc 8th World Congr Psychiatry, Athens, 12-19 October, 1989, vol 1. Amsterdam, Excerpta Medica, 1990.
11. Ochoa E, Aliño JL, Peris JC, Gracia AC: Tratamiento de deshabituacion con naltrexona en la dependencia de opiáceos. Actas Luso Esp Neurol Psiquiatr 1992:20-5:215-229.
12. Ochoa E, Arias F, Somoza JC, Ibor JL: Tratamiento con naltrexona en dependientes de opiáceos: dos años y medio de seguimiento. Arch Neurobiol 1992:55-5:224-227.
13. Hollister LE: Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report on the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry 1978:35:335-340.
14. San L, Pomarol G, Peri JM, Olle JM, Cami J: Follow-up after six months maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991;86:190,983-990.
15. Shufman EN, Porat S, Witzlum E, Gandacu D, Bar-Hamburger R, Ginath Y: The efficacy of naltrexone in preventing rcabuse of heroin after detoxification. Biol Psychiatry 1994:35: 935-945.
16. Callahan EJ, Rawson RA, McCleave B, Arias R, Glazer M, Libemtan RP: The treatment of heroin addiction: Naltrexone alone and with behaviour therapy. Int J Addict 1980; 15;795-807.
17. Stanton MD, Todd TC: The Family Therapy of Drug Abuse and Addiction. New York, The Guilford Press, 1982.
18. Azatian A, Papiasvilli A, Joseph H: A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR. J Addict Dis 1994:13:35-52.
19. Ling W, Wesson D: Naltrexone treatment for addicted health-care professionals: A collaborative private practice experience. J Clin Psychiatry 1984:45:46-48.
20. Washton AD, Pottash AC, Gold MS: Naltrexone in addicted business executives and physicians. J Clin Psychiatry 1984;45:39-41.
21. Neto D, David M: Toxicodependentes. Trata-mento combinado e por etapas. Noticias Méd 1994(suppl): 1-4;
22. Neto D, David M: Toxicodependentes. Trata-mento combinado e por etapas. Noticias Méd 1995(suppl): 1-2.
23. Neto D: Dois casos de tratamento de toxicodependentes. Evoluçâo contrària ás expectativas. Noticias Méd 1991 (suppl to No 2010):1-4.
24. Neto D, Sardinha L, David M, Cantante S: Adopçâo de heroinodependentes como estraté-gia de tratamento em ambulatorio. Apresenta-çâo de um caso. Acta Méd Port 1993;6:105-107.
25. Neto D, Sardinha L: Remissâo e maturaçâo espontáneas após paragem dos consumos, num caso de tratamento de urna heroinodepen-dente. Noticias Médicas, Lisbon, March 12 1993, pp 6-7,10.
26. Resnick RB, Washton AM, Washton NS: Psychotherapy and naltrexone in opioid dependence; in Harris LS (ed): Problems of Drug Dependence. US Dept of Health and Human Services, National Institute of Drug Abuse, 1980, NIDA Res Monogr 34, pp 109-115.
27. Graffar M: Une méthode de classification sociale d’échantillons de population. Courrier Unesco 1956;6:455.
28. Gerra G, Marcato A, Caccavari R, Fontanesi B, Delsignore R, Fertonani G, Avanzini P, Rustichelli P. Passeri M: Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995:12-1:35-41.
29. Senft RA: Experience with clonidine-naltrex-one for rapid opiate detoxification. J Subst Abuse Treat 1991:8:257-259.
30. McLellan AT, Luborskv L, Erdlen FR, LaPorte DJ: The Addiction Severity Index: A diagnostic/evaluative profile of substance abuse patients: in Gottheil E, McLellan AT. Druley KA (eds): Substance Abuse and Psychiatric Illness. New York. Pergamon Press. 1980. pp 151-159.
31. Beck AT, Ward CH, Mcndelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961:4:561-571.
32. Dcrogatis LR: Description and bibliography for the SCL-90-R and other instruments of the psychopathology rating scale series. Clin Psy-chometrRes. 1983.
33. McLellan AT, Luborskv L, Cacciola J, Griffith J, McGrahan P, O'Brien CP: Guide to the Addiction Severity Index: Background. Administration and Field Testing Results. Washington, US Govt Printing, National Institute of Drug Abuse, 1985.
34. Zanis DA, McLellan AT, Cnaan RA, Randall M: Reliability and Validity of the Addiction Severity Index with a Homeless Sample. J Subst Abuse Treat 1994; 11-6:541-548.
35. Thompson C: Affective disorders: in Thompson C (ed): The Instruments of Psychiatric Research. Chichester. Wiley. 1989. pp 87-126.
36. Bech P, Malt UF, Dencker SJ, Ahlfors UG, Eigen K, Lewander T, Lundell A, Simpson GM. Lingjaerde O: Scales for assessment of diagnosis and severity of mental disorders. Acta Psy-chiatrScand 1993;372:32-34.
37. Rogan JC, Keselnan HJ, Mendonza JL: Analysis of repeated measurements. Br J Math Stat Psychol 1979;32:269-286.
38. Koch G, Elashoff J, Amara I: Repeated measurements: Design and analysis; in Kotz S, Johnson NL (eds): Encyclopaedia of Statistical Sciences. New York, Wiley, 1981. vol 8.
39. Norusis M: Storing Memories: Repeated Measures Analysis of Variance. Advanced Statistics SPSS. Chicago, SPSS Inc, 1986.
40. Schcctcr A: Clinical use of naltrexone (ENI639A). II. Experience with 50 patients in a New York treatment clinic. Am J Drug Alcohol Abuse 1975;2:433-442.
41. Julius D, Renault P (eds): Narcotic Antagonists: Naltrexone Progress Report. NIDA Research Monograph No 9. Washington, US Public Health Service, US Government Printing Office, 1976.
42. Judson BA, Carney TM, Goldstein A: Naltrexone treatment of heroin addiction: Efficacy and safety in a double-blind dosage. Comp Drug Alcohol Depend 1981;7:325-346.